arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

aTYR PHARMA INC

ATYR
$6.17 0.00 (+0.08%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
52 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

aTYR PHARMA INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $605.1M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -17.6% ↘
FCF / Share $-0.10 ↗
Trailing P/E —
Price / Book 12.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-10.31M
↑ +47.2% —
Operating Margin Operating profit as % of sales
-76.5%
↑ +68.2% —
FCF / Share Free cash flow per share
$-0.10
↑ +25.6% —
Long-Term Debt Long-term obligations
$2.74M
↓ -40.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
8
Financial Health ↓
5
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters